Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Nova Ltd (NVMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Nova Ltd — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Nova Ltd trades at $325.85 (market cap $10.89B). The key difference: Nova Ltd is the larger of the two by market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Nova Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Nova Ltd for 6 Days on average.
| KYMR | NVMI | |
|---|---|---|
Market Cap | $8.87B | $10.89B |
Volume | 779,107 | 416,153 |
Sector | Health | Technology |
52-Week High | $127.31 | $605.65 |
52-Week Low | $55.80 | $275.78 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $8.26B | $10.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NVMI trades at $342.37, up 0.58% on the day, with a bearish technical signal driven by moving averages but supported by strong fundamentals including a 28.84% net income margin and three consecutive quarterly earnings beats. The stock is positioned near its pivot point of $344, with immediate support at $336. Revenue growth is projected to increase from $881 million in 2025 to $937 million in 2026, though net cash flow turned negative in 2026.
The outlook remains positive given the 85.7% analyst buy rating and a consensus price target of $556.50, implying significant upside. Key risks include high valuation multiples like a P/E of 42.64 and negative cash flow trends, but the company's tool-of-record status in AI chip packaging provides a durable growth catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Nova Ltd
Nova provides metrology solutions for semiconductor manufacturing. Its systems measure material and process characteristics to help chipmakers control production across advanced nodes and packaging.
Read more on NVMI →
